Stock OXIS INTERNATIONAL
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Oxis International Stock OTC Bulletin Board

Equities

US6918295014

Pharmaceuticals

Financials

Sales 2022 - Sales 2023 - Capitalization 10.56M 14.39M
Net income 2022 -20M -27.25M Net income 2023 -7M -9.54M EV / Sales 2022 -
Net cash position 2022 16.33M 22.26M Net cash position 2023 13.91M 18.96M EV / Sales 2023 -
P/E ratio 2022
-1.35 x
P/E ratio 2023
-1.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.34%
More Fundamentals * Assessed data

Chart Oxis International

Dynamic Chart

Latest news about Oxis International

Top Midday Decliners MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Top Premarket Gainers MT
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Analyst Recommendations on Oxis International

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
More recommendations

Press releases Oxis International

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results AQ
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS AQ
More press releases

News in other languages on Oxis International

Caterpillar deja París, el cacao está menos caliente
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud
More news

Managers and Directors - Oxis International

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 61 21-01-12
Manu Ohri DFI
 Director of Finance/CFO 68 22-02-17
Jeffrey Miller PRN
 Corporate Officer/Principal - 22-12-13
Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 23-04-30
Bruce Wendel BRD
 Director/Board Member 70 20-11-10
Rajesh Shrotriya BRD
 Director/Board Member 79 21-01-12
More insiders

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-06-25 - Annual General Meeting
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Stock